Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from...

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial...

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate...

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate...

INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity,...

LEHI, Utah., Sept. 12, 2024. Biolexis Therapeutics, a biopharmaceutical company pioneering next-generation weight loss treatments, today announced the...

Lowering the dose of anti-cancer drugs well below the standard treatment threshold has shown promise in improving tumours’ response to...

Lowering the dose of anti-cancer drugs well below the standard treatment threshold has shown promise in improving tumours’ response to...

FRIDAY, Sept. 6, 2024 -- Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with...

Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.